Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2019-08-16 Legal Proceedings Report
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
EUROPEAN MEDICINES AGENCY VALIDATES MARKETING APPLICATION FOR FILGOTINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
Legal Proceedings Report Classification · 99% confidence The document is a press release announcing that the Marketing Authorization Application (MAA) for the drug filgotinib has been validated by the European Medicines Agency (EMA) for the treatment of rheumatoid arthritis. It details clinical trial data (FINCH program) and mentions future plans (US NDA submission). This type of announcement, focusing on regulatory milestones and clinical progress, is characteristic of an Earnings Release (ER) or a general press release about corporate/product development. Since it is an initial announcement of a significant regulatory event (validation of MAA) and not a comprehensive financial report (10-K, IR) or a transcript (CT), the most fitting category is Earnings Release (ER), as these often include key operational and regulatory updates alongside or instead of quarterly financial figures. It is not a Report Publication Announcement (RPA) because it contains substantive news, not just a notice that a report is available. It is not a Legal Proceedings Report (LTR) as this is a regulatory submission, not a lawsuit update. Given the context of drug development milestones, ER is the best fit among the provided options for a major operational update press release.
2019-08-16 English
EUROPEES GENEESMIDDELENBUREAU VALIDEERT INDIENING VERGUNNINGSDOSSIER VOOR FILGOTINIB VOOR DE BEHANDELING VAN REUMATOÏDE ARTRITIS
Regulatory Filings Classification · 95% confidence The document is a press release issued by Gilead Sciences and Galapagos NV announcing that the European Medicines Agency (EMA) has validated their marketing authorization application for the drug filgotinib. It provides details on the clinical trial results (FINCH studies), regulatory status, and contact information for investors and media. While it contains corporate information, it is a standard corporate press release announcing a regulatory milestone. According to the 'Menu vs Meal' rule, since this is a press release announcing a development and includes a link to a PDF version of the release, it falls under the category of a general regulatory announcement or press release.
2019-08-15 Dutch
EUROPEES GENEESMIDDELENBUREAU VALIDEERT INDIENING VERGUNNINGSDOSSIER VOOR FILGOTINIB VOOR DE BEHANDELING VAN REUMATOÏDE ARTRITIS
Regulatory Filings Classification · 95% confidence The document is a press release issued by Gilead Sciences and Galapagos NV announcing that the European Medicines Agency (EMA) has validated their marketing authorization application for the drug filgotinib. It provides details on the clinical trial results (FINCH studies), regulatory status, and contact information for investors and media. While it contains corporate information, it is a standard corporate press release announcing a regulatory milestone. According to the 'Menu vs Meal' rule, since this is a press release announcing a development and includes a link to a PDF version of the release, it falls under the category of a general regulatory announcement or press release.
2019-08-15 Dutch
EUROPEES GENEESMIDDELENBUREAU VALIDEERT INDIENING VERGUNNINGSDOSSIER VOOR FILGOTINIB VOOR DE BEHANDELING VAN REUMATOÏDE ARTRITIS
Regulatory Filings Classification · 95% confidence The document is a press release issued by Gilead Sciences and Galapagos NV announcing that the European Medicines Agency (EMA) has validated their marketing authorization application for the drug filgotinib. It provides details on the clinical trial results (FINCH studies), regulatory status, and contact information for investors and media. While it contains corporate information, it is a standard corporate press release announcing a regulatory milestone. According to the 'Menu vs Meal' rule, since this is a press release announcing a development and includes a link to a PDF version of the release, it falls under the category of a general regulatory announcement or press release.
2019-08-15 Dutch
EUROPEES GENEESMIDDELENBUREAU VALIDEERT INDIENING VERGUNNINGSDOSSIER VOOR FILGOTINIB VOOR DE BEHANDELING VAN REUMATOÏDE ARTRITIS
Regulatory Filings Classification · 95% confidence The document is a press release issued by Gilead Sciences and Galapagos NV announcing that the European Medicines Agency (EMA) has validated their marketing authorization application for the drug filgotinib. It provides details on the clinical trial results (FINCH studies), regulatory status, and contact information for investors and media. While it contains corporate information, it is a standard corporate press release announcing a regulatory milestone. According to the 'Menu vs Meal' rule, since this is a press release announcing a development and includes a link to a PDF version of the release, it falls under the category of a general regulatory announcement or press release.
2019-08-15 Dutch
EUROPEAN MEDICINES AGENCY VALIDATES MARKETING APPLICATION FOR FILGOTINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
Regulatory Filings Classification · 95% confidence The document is a press release issued by Gilead Sciences and Galapagos NV announcing the validation of a Marketing Authorization Application (MAA) for a drug candidate (filgotinib) by the European Medicines Agency. It contains standard corporate contact information, forward-looking statements, and a link to download the PDF version of the release. Since it is a general corporate announcement regarding regulatory progress and not a formal financial report, audit, or specific governance filing, it falls under the 'Regulatory Filings' (RNS) category as a general regulatory announcement.
2019-08-15 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.